Refining CAR-NK Design
Preclinical findings suggest that receptor design and timed kinase inhibition could help strengthen next-generation cell therapies.
-
1
Researchers are enhancing CAR-NK cell therapies by modifying receptor architecture and controlling drug exposure.
-
2
CD19-targeted CAR-NK-92 cells showed antigen-specific killing of CD19-positive leukemia and lymphoma cell lines.
-
3
Transcriptional profiling revealed that different CAR configurations engage NK-associated activation programs variably.
-
4
Transient exposure to dasatinib suppressed CAR-NK activity but increased cytotoxicity and cytokine production post-withdrawal.
-
5
The study suggests that receptor engineering and pharmacologic modulation can improve next-generation allogeneic NK products.
